Abstract: The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Abstract: The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Abstract: The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Abstract: The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Abstract: The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Abstract: A wearable sensor apparatus comprises a motion sensor configured to sense two or three dimensional movement and orientation of the sensor and a vibration sensor configured to sense acoustic vibrations. The apparatus includes means for attaching the motion sensor and the vibration sensor to a body. The sensor apparatus enables long term monitoring of mechanomyographic muscle activity in combination with body motion for a number of applications.

Abstract: The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Abstract: The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Abstract: A wearable sensor apparatus comprises a motion sensor configured to sense two or three dimensional movement and orientation of the sensor and a vibration sensor configured to sense acoustic vibrations. The apparatus includes means for attaching the motion sensor and the vibration sensor to a body. The sensor apparatus enables long term monitoring of mechanomyographic muscle activity in combination with body motion for a number of applications.

Abstract: A wearable sensor apparatus comprises a motion sensor configured to sense two or three dimensional movement and orientation of the sensor and a vibration sensor configured to sense acoustic vibrations. The apparatus includes means for attaching the motion sensor and the vibration sensor to a body. The sensor apparatus enables long term monitoring of mechanomyographic muscle activity in combination with body motion for a number of applications.

Abstract: The present invention includes a composition comprising a compound, such as a 2,4,6-triamino-1,3,5-triazine, 2,4,6-triaminopyrimidine, 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine or 2,4-diamino-7H-pyrrolo[2,3-d]pyrimidine, that is useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention. The present invention further includes a method of preventing destabilizing or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention.

Abstract: The present invention includes a composition comprising a compound, such as a 2,4,6-triamino-1,3,5-triazine, 2,4,6-triaminopyrimidine, 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine or 2,4-diamino-7H-pyrrolo[2,3-d]pyrimidine, that is useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention. The present invention further includes a method of preventing destabilizing or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention.

Abstract: In one embodiment of the invention, an object oriented autorouter is disclosed for routing nets in a circuit. The object oriented autorouter includes a routing data model (RDM); at least one routing engine, such as a single connection router (SCR), a topographical (TOPO) transformation engine, and a detail geometric (DETAIL) engine, and a command and control module (CCM) coupled together. The RDM reads and write data with a design database as well as reading one or more object oriented design constraints. Each of the routing engines have at least one action to operate on the design database to improve compliance of the circuit to a constraint. The CCM controls the overall routing process of the nets in the circuit and includes at least one director to invoke at least one of the routing engines to achieve compliance with one or more constraints.

Abstract: The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

Abstract: Local constraints on placement of routing objects for direct connections between terminals in a circuit layout are determined from global constraints on the placement of the routing objects in a process referred to as global constraint budgeting. An autorouter finds paths in the layout to satisfy the local constraints and ignores the global constraints. The local constraints are updated before each routing pass to ensure that routes are completed on individual direct connections while also satisfying the global constraint.

Abstract: The present invention includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (+)-doxapram or a salt thereof, and a pharmaceutically acceptable carrier, wherein the formulation is essentially free of (?)-doxapram or a salt thereof.

Abstract: An approach is provided for selectively optimizing a circuit design to be physical implemented. The approach includes generating a circuit routing solution in accordance with a plurality of constraints for parametric resources of the circuit design, with the constraints being defined respectively by a plurality of corresponding constraint instances. Each constraint instance variably indicates an effective constraining limit and degree of consumption for at least one of the parametric resources. At least one of the constraints is selectively adjusted by a predetermined over-constraining amount, and the circuit routing solution is preliminarily modified by applying at least one routing action selected responsive to the constraint adjustment. An automatic evaluation is then made of the potential impact upon constraint compliance.

Abstract: In one embodiment of the invention, an object oriented autorouter is disclosed for routing nets in a circuit. The object oriented autorouter includes a routing data model (RDM); at least one routing engine, such as a single connection router (SCR), a topographical (TOPO) transformation engine, and a detail geometric (DETAIL) engine, and a command and control module (CCM) coupled together. The RDM reads and write data with a design database as well as reading one or more object oriented design constraints. Each of the routing engines have at least one action to operate on the design database to improve compliance of the circuit to a constraint. The CCM controls the overall routing process of the nets in the circuit and includes at least one director to invoke at least one of the routing engines to achieve compliance with one or more constraints.

Abstract: An approach is provided for selectively optimizing a circuit design, including generating a circuit routing solution according to a plurality of constraints for parametric resources of the circuit design, with the constraints being defined respectively by a plurality of corresponding constraint instances. Each constraint instance variably indicates an effective constraining limit and degree of consumption for at least one of the parametric resources. At least one of the constraints is selectively adjusted by a predetermined over-constraining amount, and the circuit routing solution is preliminarily modified by applying at least one routing action selected responsive to the constraint adjustment. The potential impact upon constraint compliance is evaluated, including generating a relative cost measure for the preliminary modification of the circuit routing solution, based at least partially upon each of the constraint instances.

Abstract: Local constraints on placement of routing objects for direct connections between terminals in a circuit layout are determined from global constraints on the placement of the routing objects in a process referred to as global constraint budgeting. An autorouter finds paths in the layout to satisfy the local constraints and ignores the global constraints. The local constraints are updated before each routing pass to ensure that routes are completed on individual direct connections while also satisfying the global constraint.